厄洛替尼对比依托泊苷/顺铂联合同步放疗治疗不可切除Ⅲ期EGFR突变阳性非小细胞肺癌:多中心随机开放标签2期试验
这项多中心随机开放标签2期试验比较厄洛替尼联合同步放疗(E+RT)与依托泊苷/顺铂联合同步放疗(EP+RT)在不可切除ⅢA/B期EGFR突变阳性非小细胞肺癌中的疗效。主要终点达到,但 definitive 结论受限。
要点
- 样本量小(每组20例),无法做出确定性疗效结论。
核心结论
- E+RT相比EP+RT显著延长了不可切除Ⅲ期EGFR突变阳性NSCLC患者的中位PFS,且耐受性相似。
- 由于样本量小和入组缓慢,无法对E+RT的疗效做出确定性结论,且3期研究可能不可行。
研究设计与样本
- 多中心、随机、开放标签、2期试验,中国19家机构参与,2012年12月至2016年1月。
- E+RT方案:口服厄洛替尼150 mg/d持续2年或至疾病进展/不可耐受毒性,放疗200 cGy/d,每周5天,共6周,从厄洛替尼首日开始。
- EP+RT方案:依托泊苷50 mg/m2静脉第1-5天和第29-33天;顺铂50 mg/m2静脉第1、8、29、36天;放疗同E+RT组。
- 主要终点为无进展生存期(PFS),次要终点包括客观缓解率和安全性。
主要发现
- 任何级别不良事件发生率在E+RT组和EP+RT组分别为88.9%和84.2%,组间相似。
关键数值与推荐
- 任何级别不良事件发生率E+RT组88.9% vs EP+RT组84.2%。
临床怎么用
- 对于不可切除Ⅲ期EGFR突变阳性NSCLC,E+RT可能作为EP+RT之外的同步治疗选择,但需个体化评估。
- E+RT组PFS获益显著,但样本量小,不能替代标准治疗决策。
- 两组耐受性相似,E+RT方案(厄洛替尼口服150 mg/d联合放疗)可考虑用于适合患者。
局限性
- 每组仅20例患者,样本量小,统计效能有限。
- 开放标签设计可能引入偏倚。
- 患者入组缓慢,可能影响研究结果的普遍性,且3期试验不可行。
- 无法对E+RT的疗效做出确定性结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to compare erlotinib (E) and etoposide/cisplatin (EP) with concurrent radiation therapy (RT) for patients with stage IIIA/B unresectable advanced non-small cell lung cancer with activating epidermal growth factor receptor mutation (EGFRm+). METHODS AND PATIENTS: This was a multicenter, randomized, open-label, phase 2 trial conducted across 19 institutions in China (December 2012 to January 2016). Enrolled patients were randomized (1:1) to E + RT (oral erlotinib 150 mg/d for 2 years or until disease progression or intolerable toxicity and RT 200 cGy/d, 5 d/wk for 6 weeks from the first day of erlotinib) or EP + RT (etoposide 50 mg/m2 intravenously on days 1-5 and 29-33; cisplatin 50 mg/m2 intravenously on days 1, 8, 29 and 36; and RT as for E + RT). The primary endpoint was progression-free survival (PFS). Secondary endpoints included objective response rate and safety. RESULTS: Two hundred fifty-two patients were screened, and 20 patients with EGFRm+ in each group received the allocated E + RT or EP + RT treatment. Patient characteristics were well balanced between groups. Compared with EP + RT, median PFS with E + RT was significantly longer (24.5 vs 9.0 months [hazard ratio, 0.104; 95% confidence interval, 0.028-0.389; P < .001]). Objective response rate in the E + RT and EP + RT groups was 70% and 61.9%, respectively (P = .744). The incidence of adverse events (any grade) was similar between E + RT and EP + RT groups (88.9% and 84.2%). CONCLUSIONS: The primary endpoint of PFS was met, and the data showed that E + RT might provide PFS improvement compared with EP + RT, with similar tolerability. However, definitive statements regarding the efficacy of concurrent E + RT in patients with unresectable stage III non-small cell lung cancer with activating EGFRm+ cannot be made, and slow patient accrual will likely make it infeasible to conduct a phase 3 study.
引用
- Xing L, Wu G, Wang L, et al. Erlotinib Versus Etoposide/Cisplatin With Radiation Therapy in Unresectable Stage III Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter, Randomized, Open-Label, Phase 2 Trial. Int J Radiat Oncol Biol Phys. 2020. PMID: 33220395. doi:10.1016/j.ijrobp.2020.11.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。